ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference

Rhea-AI Summary

ProKidney Corp (Nasdaq: PROK), a late clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD), announced its participation in two major healthcare conferences this November. The company will present at the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 13, 2024, at 10:30am ET, and the Jefferies London Healthcare Conference on November 20, 2024, at 10:00am GMT.

Both presentations will be in a fireside chat format, with live webcasts available through ProKidney's website. Replays will be accessible for 90 days after the events. The management team will also conduct one-on-one meetings with investors during both conferences.

News Market Reaction – PROK

+3.85%

+3.85% Session move

In the trading session that priced this news, PROK gained 3.85%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WINSTON-SALEM, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in two upcoming healthcare conferences in November.

Guggenheim Inaugural Healthcare Innovation Conference (Boston)
Date:	Wed, November 13, 2024
Time:	10:30am ET
Format:	Fireside Chat
Webcast:	Link
Jefferies London Healthcare Conference
Date:	Wed, November 20, 2024
Time:	10:00am GMT
Format:	Fireside Chat
Webcast:	Link

The live webcasts will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of each event, a replay will be available for 90 days.

The ProKidney management team will also host one-on-one meetings during these events. Interested investors should contact their Guggenheim and Jefferies representatives to schedule meetings.

About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit www.prokidney.com.

Investor Contacts:

ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com

LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com

FAQ

When is ProKidney (PROK) presenting at the Guggenheim Healthcare Conference in 2024?

ProKidney (PROK) is presenting at the Guggenheim Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 10:30am ET in Boston.

What conferences is ProKidney (PROK) attending in November 2024?

ProKidney (PROK) is attending two conferences: the Guggenheim Inaugural Healthcare Innovation Conference in Boston and the Jefferies London Healthcare Conference.

How long will ProKidney's (PROK) conference webcasts be available for replay?

The webcasts from both conferences will be available for replay for 90 days following the completion of each event on ProKidney's website.

What time is ProKidney's (PROK) presentation at the Jefferies London Healthcare Conference?

ProKidney (PROK) is scheduled to present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 10:00am GMT.